Effectiveness of nephroprotective therapy in children with chronic pyelonephritis in the follow-up observation

L.I. Vakulenko

Abstract


Background. Timely correction of hemodynamic disorders in children with chronic pyelonephritis is a component of nephroprotection. Аngiotensin-converting enzyme inhibitors (ACEI) are the basis of renoprotective therapy. The purpose of the study was to evaluate the efficiency of nephroprotective therapy in children with chronic pyelonephritis during follow-up observation. Materials and methods. Ninety three children aged 4 to 17 years with chronic pyelonephritis (disease duration from 3 to 7 years) were examined. The control group consisted of 30 healthy children of the same age. Daily blood pressure monitoring and Doppler sonography of the renal blood vessels were performed. Furthermore, ACEI enalapril was administered in the maximum allowed and tolerated doses, for 2–3 years. Results. During the follow-up examination, there was a significant reduction in the incidence and severity of hypertension syndrome according to the data of daily blood pressure monitoring on the background of ACEI administration (vs baseline from 28.5 to 7 % in general; p < 0.05). Moreover, there were reliable changes of renal hemodynamic parameters at the level of segmental and stem arteries in the form of reduced peripheral resistance parameters and rate indices that indicated the processes of vessel remodeling in the kidneys. In the prospective analysis, there has been determined an improvement of intrarenal hemodynamics on the background of ACEI administration. Conclusions. Chronic pyelonephritis in children is associated with gradual disorders of the central and peripheral blood flow, ischemic and hemodynamic changes in parenchyma that require proper correction. ACEI enalapril is a drug of choice. Moreover, enalapril inclusion in the treatment leads to positive dynamics in majority of patients (75.2 %).


Keywords


children; chronic pyelonephritis; renal hemodynamics; daily blood pressure monitoring; hypertension; nephroprotection; angiotensin-converting enzyme inhibitors

References


Ivanov DD. Next step in chronic kidney disease therapy. Počki. 2016;(16):10-13. doi: 10.22141/2307-1257.2.16.2016.72205. (in Russian).

Makjejeva NI. Renocardial continuum in children with chronic kidney disease: "traditional" and "non-traditional" risk factors for the formation of cardiovascular complications. Pediatriya, Akusherstvo ta Ginekologiya. 2013;(455):20-24. (in Ukrainian).

Vidi SR. Role of hypertension in progression of chronic kidney disease in children. Curr Opin Pediatr. 2018 Apr;30(2):247-251. doi: 10.1097/MOP.0000000000000595.

Hooman N, Isa-Tafreshi R, Mostafavi SH, Hallaji F, Tavasoli A, Otukesh H. The prevalence of hypertension in children with renal scars. Minerva Pediatr. 2017 Jun;69(3):200-205. doi: 10.23736/S0026-4946.16.04217-1.

Halbach S, Flynn J. Treatment of hypertension in children with chronic kidney disease. Curr Hypertens Rep. 2015 Jan;17(1):503. doi: 10.1007/s11906-014-0503-3. 

Flynn JT, Mitsnefes M, Pierce C, et al. Blood pressure in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children study. Hypertension. 2008 Oct;52(4):631-7. doi: 10.1161/HYPERTENSIONAHA.108.110635.

Mitsnefes M, Flynn J, Cohn S, et al. Masked hypertension associates with left ventricular hypertrophy in children with CKD. J Am Soc Nephrol. 2010 Jan;21(1):137-44. doi: 10.1681/ASN.2009060609. 

Tian J, Niu L, An X. Cardiovascular risks in chronic kidney disease pediatric patients. Exp Ther Med. 2017 Nov;14(5):4615-4619. doi: 10.3892/etm.2017.5117.

Gallibois CM, Jawa NA, Noone DG. Hypertension in pediatric patients with chronic kidney disease: management challenges. Int J Nephrol Renovasc Dis. 2017 Jul 26;10:205-213. doi: 10.2147/IJNRD.S100891.

ESCAPE Trial Group, Wühl E, Trivelli A, et al. Strict blood-pressure control and progression of renal failure in children. N Engl J Med. 2009 Oct 22;361(17):1639-50. doi: 10.1056/NEJMoa0902066.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013 Jan;3(1):1–150. doi: 10.1038/kisup.2012.76.

Ivanov DD, Kuryata OV, Garmysch IP. Renin angiotensin-aldosterone system blockers: chronic kidney disease and cardiovascular risk. Počki. 2018;7(2):81-90. doi: 10.22141 /2307-1257.7.2.2018.127393. (in Russian).

Horowitz B, Miskulin D, Zager P. Epidemiology of hypertension in CKD. Adv Chronic Kidney Dis. 2015 Mar;22(2):88-95. doi: 10.1053/j.ackd.2014.09.004. 

Zorin ІV, Vialkova AA. Prevention of progression of chronic kidney disease in children with reflux-nephropathy. Lechaschi Vrach. 2015;(1):59. (in Russian).

Nagornaia NV, Parshin SA. ACE inhibitors: possibility of application in pediatric practice. Zdorovʹe rebenka. 2010;(24):110-115. (in Russian).

Ivanov DD, Korzh OM. Nefrologija v praktyci simejnogo likarja: navchal'no-metodychnyj posibnyk [Nephrology in the practice of a family doctor: educational and methodical manual]. 2nd ed. Donetsk: Publisher Zaslavsky OYu; 2012. 400 р. (in Ukrainian).

Ruggenenti P, Cravedi P, Chianca A, Caruso M, Remuzzi G. Achieving remission of proteinuria in childhood CKD. Pediatr Nephrol. 2017 Feb;32(2):321-330. doi: 10.1007/s00467-016-3495-1.

Webb NJ, Shahinfar S, Wells TG, et al. Losartan and enalapril are comparable in reducing proteinuria in children. Kidney Int. 2012 Oct;82(7):819-26. doi: 10.1038/ki.2012.210.

Zaitcev II, Alexandrov DA. Renoprotective effect of angiotensin converting enzyme ingibitorin children with renal diseases. Medical Journal. 2013;(44):87-89. (in Russian).

Cravedi P, Ruggenenti P, Remuzzi G. Which antihypertensive drugs are the most nephroprotective and why? Expert Opin Pharmacother. 2010 Nov;11(16):2651-63. doi: 10.1517/14656566.2010.521742.

Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics. 2017 Sep;140(3). pii: e20171904. doi: 10.1542/peds.2017-1904.




DOI: https://doi.org/10.22141/2224-0551.13.2.2018.129549

Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 CHILD`S HEALTH

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта